Our Mission

Our Story

Therapeutic Areas

Leadership

Kite Locations

Our Cell Therapy Technology

Our Therapies

Pipeline

Trials & Expanded Access

External Research Program (ERP)

Patient Stories

Our Authorized Treatment Centers

Kite Konnect

Newsroom

Press Releases

Company Statements

NICE Recommends Expanded and Earlier Use of Kite CAR T-cell Therapy to Treat Certain Types of Blood Cancer

Kite’s Yescarta® First CAR T-cell Therapy to Receive Health Canada Authorization for Use as Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma

Christi Shaw to Depart Gilead and Kite Leadership End of Q1

Kite’s Yescarta® is First Car T-Cell Therapy Recommended for Routine Use in England, United Kingdom

Kite Expands Cell Therapy Manufacturing Operations in Maryland

Supreme Court Denied Juno’s Appeal Request in Juno vs. Kite Case

Kite Receives U.S. Food and Drug Administration (FDA) Orphan Drug Designation for KITE-222 for Acute Myeloid Leukemia

Kite Launches CAR T-cell Therapy Operations in Brazil, Singapore and Saudi Arabia

Kite Announces U.S. FDA Clearance of Investigational New Drug Application for Kite-363, a Dual-Targeting CAR T-Cell Therapy Candidate for Large B-Cell Lymphoma

Kite’s Yescarta® (Axicabtagene Ciloleucel) Car T-Cell Therapy Now Widely Available and Publicly Funded for Patients in Australia with Four Types of Aggressive Non-Hodgkin Lymphoma

Kite Announces U.S. FDA Clearance of Investigational

Media Kit

Now Hiring

Careers at Kite

Manufacturing Careers at Kite

Early Talent Programs at Kite

Culture & Benefits

Investor Relations

Contact Us

Kite Konnect®